Advertisement

Organisation › Details
Laboratoires Servier, Les
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of €4.2 billion in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) into research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, cancer and metabolism, immune-inflammatory and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. *
![]() |
Start | 1954-01-01 established |
Group | Servier (Group) | |
![]() |
Industry | pharmaceutical |
![]() |
Person | Seta, Jean-Philippe (Servier 2003–201310 CEO joined Servier 1984 LEFT 201310) |
![]() |
Region | Suresnes |
Country | France | |
Street | 50 rue Carnot | |
City | 92284 Suresnes Cedex | |
Tel | +33-1-5572-6000 | |
Address record changed: 2014-11-26 | ||
Basic data | Employees | H: 10,001 to 50,00 (2019-06-05) |
Currency | EUR | |
Annual sales | 4,200,000,000 (turnover, consolidated (2018) 2018-12-31) | |
* Document for �About Section�: Yposkesi. (6/5/19). "Press Release: Servier Appoints Yposkesi for Lentiviral Vector GMP-Manufacturing in CAR-T Cell Development Technology". Suresnes & Corbeil-Essonnes. | ||
Record changed: 2019-11-09 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for Servier (Group)
- [1] Yposkesi. (6/5/19). "Press Release: Servier Appoints Yposkesi for Lentiviral Vector GMP-Manufacturing in CAR-T Cell Development Technology". Suresnes & Corbeil-Essonnes....
- [2] OSE Immunotherapeutics S.A.. (2/7/19). "Press Release: OSE Immunotherapeutics and Servier Announce First Option within Global License Agreement Exercised for further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases"....
- [3] Allogene Therapeutics, Inc.. (1/28/19). "Press Release: Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy". South San Francisco, CA & Paris....
- [4] Allogene Therapeutics, Inc.. (12/3/18). "Press Release: Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia". South San Francisco, CA & Paris....
- [5] Allogene Therapeutics, Inc.. (11/1/18). "Press Release: Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting". South San Francisco, CA....
- [6] GeNeuro S.A.. (9/18/18). "Press Release: GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier". Paris & Geneva....
- [7] Allogene Therapeutics, Inc.. (9/6/18). "Press Release: Allogene Therapeutics Completes a $120 Million Private Financing". South San Francisco, CA....
- [8] Servier. (4/16/18). "Press Release: Servier Acquires Shire’s Oncology Business to Gain Direct Commercial Access in the US". Paris....
- [9] GeNeuro S.A.. (12/21/17). "Press Release: GeNeuro To Receive €12 Million Milestone Payment from Servier for Final Patient Visit in GNbAC1 CHANGE-MS Phase 2b Study". Geneva....
- [10] Servier. (12/13/17). "Press Release: Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top